Plan ahead

Plan ahead of these events, and schedule time with us!

We can help you:


Understand the landscape in seconds for the targeted therapy of your choice.

Book a demo

To book a live demo to show you how this works specifically to your questions.

Events Beacon will be attending

3rd World ADC Asia 2024

June 25 – 27, 2024 |  Incheon, South Korea

The year 2024 has been considered the ‘coming of age’ era for antibody-drug conjugates, in great part due to the remarkable resurgence in drug development across the Asia-Pacific region. This part of the world is taking the ADC industry by storm with high-profile deals, multiple approvals, multiple ADCs moving into clinical trials, and novel targets being explored just to name some advancements.

Back by popular demand after a short break, the 3rd World ADC Asia is bringing together pioneers and key opinion leaders across mega-pharma and biotechnology focusing on China, Japan, Taiwan, South Korea and Singapore. They’ll be sharing their most pressing challenges, novel payloads, conjugationand linker innovations to inform ADC development and improve targeting accuracy.

Alongside a phenomenal speaker faculty, our ADC Technical Lead and Researcher, Jia He, will be exploring the flourishing landscape. Taking time to review the clinical and preclinical space, and analyzing trends in this recent flurry of ADC deals, this is one not to be missed! Uncover the full presentation details today.

Find out more

4th Oligonucleotides for CNS Summit 2024

July 9 – 11, 2024 |  Boston, MA

In a landscape where traditional treatments often fall short, oligonucleotide therapeutics emerge as game-changers offering precise targeting and potentially life-altering outcomes.

The 4th Oligonucleotides for CNS Summit is the only forum wholly dedicated to unique challenges and neuroscience innovation for this modality; delving into the hottest ASO, siRNA, saRNA, and miRNA program updates and latest industry challenges.

This July, Beacon’s RNA Senior Research Analyst, Ioana Panait, joins 50+ senior industry leaders across the space to explore the oligonucleotide therapy development for neurological disorders landscape. Discover the full presentation breakdown here! Make sure to add this pivotal event to your calendar today.

Find out more

9th Microbiome Movement Drug Development Summit 2024

July 10 – 12, 2024 |  Boston, MA

As landmark Ferring & Seres Therapeutics approvals prove the safety of the microbiome modality, robust clinical efficacy data for disease beyond infectious is now paramount to reinvigorate investment across the community.

The 9th Microbiome Movement Drug Development Summit returns as the industry’s trusted, definitive forum for the global network of microbial therapeutic developers. It ensures teams can stay ahead of the curve to robustly prove clinical efficacy as regulator and investor scrutiny necessitates more compelling data than ever before.

We are proud to be a part of this year’s speaker faculty, and bring insights you can help to strategize! Align your pipeline strategy with key industry leaders in the US and across the globe where investment and collaborations are shaping the future of microbiome drug development. Find Beacon’s Ada Lam’s, Research Analyst, full presentation synopsis and presentation details here!

Find out more

4th Induced Proximity-Based Drug Discovery Summit 2024

July 23 – 25, 2024 |  Boston, MA

As recent advances in next-generation induced proximity modalities progress from the bench to the clinic, the 4th Induced Proximity-Based Drug Discovery Summit returns with 3 days of jam-packed insights to address your burning questions, including:

  • How to identify and validate suitable chemical targets for non-degrading heterobifunctional and monovalent drugs?
  • How to accelerate the hit discovery of novel binders and ligands?
  • How can advanced computing supplement the rational design and discovery of potent and selectively induced proximity modalities?
  • How to elucidate the intricate cellular biology, regulatory mechanisms, and protein chemistry governing ternary complex formation?
  • What are the design principles for developing targeted stabilization, modulation, post-translational modification, and degrading small molecules and biologics?

We are uniting with 100+ large and small-molecule drug discovery experts, to review the induced proximity Landscape to spark novel and continued opportunities for therapeutic intervention. Join our TPD Research Analyst, Katie Spooner, as she reviews the induced proximity landscape to spark novel & continued opportunities for therapeutic intervention! Discover the full presentation details here.

Find out more

3rd Cell Therapy Analytical Development Summit Europe

September 3 – 5, 2024 | London, UK

With regulatory bottlenecks significantly delaying the process of characterisation to method validation and release, the European cell therapy community is actively seeking a central hub to collaborate, connect and share insights to drive the future development of cell therapies forward.

Returning to London this September, the 3rd Cell Therapy Analytical Development Summit Europe is the definitive summit dedicated to defining and refining analytics to ensure the swift progression of highly efficacious products through IND/IMPD and clinical trials.

Uniting pioneering analytical development and quality control experts from Achilles Therapeutics, Avobis Bio, Bristol Myers Squibb, Johnson & Johnson, GSK, and MHRA, this summit is your one-stop shop to spearhead the future of analytical innovation. 

Discover the full 3-day agenda details here.

Find out more

15th World Bispecific Summit 2024

September 3 – 5, 2024 | Boston, MA

The 15th World Bispecific Summit has established itself as the key biopharma-directed event to gain clear insights into the latest advancements and future directions amongst the mass of bispecific antibodies currently being developed and how to address associated development challenges encountered within this therapeutic modality.

If your research teams are looking to keep ahead of the next wave of bispecific antibodies currently in development, join this event to learn how experts are leveraging pioneering new formats like bispecific ADCs and exciting targets like peptide-HLA complexes whilst managing developability and risk.

Presenting ‘A Review of the Bispecific Landscape: The Past, The Present & The Future of Biologics’ our Research Analyst, Flavio Lima Bianchi will be reviewing drug and trial landscapes, discussing the emerging trends in the space, and looking towards the future of the bispecific industry.

Discover the 3-day agenda and Flavio’s talk in more detail here.

Find out more

ADC & Radiopharmaceuticals Pharma & Biotech Partnering Summit 2024

September 9 – 10, 2024 | Boston, MA

Major moves in the pharma and biotech partnering are reshaping the landscape. With AbbVie’s acquisition of ImmunoGen leading the charge in 2023, and Merck’s licensing deal with Daiichi reaching unprecedented heights across three ADC programs, the market frenzy surrounding ADCs has never been hotter.

How does one differentiate and obtain assets poised for clinical success in the next wave of deals?

Enter the ADC & Radiopharmaceuticals Pharma & Biotech Partnering Summit. This event cuts through the noise of partnership events to gather a targeted critical mass of 100+ ADC companies.

It provides a platform for networking and fast-tracking the search and evaluation of earlier development assets. By significantly improving the alignment, efficiency, and yield of conversations, this summit empowers participants to navigate the complex partnering landscape with confidence.

Beacon is set to join the expert speaker faculty, to deliver an analysis of clinical data and deals & company landscape across the ADCs & Radiopharmaceuticals market; with more data shared than ever before, this is not one to be missed! Find out more about our talk here.

Find out more